Article

Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation

2024-06-02

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease, initiated predominantly by mutations in Kras , which induce acinar-to-ductal metaplasia (ADM) and subsequent formation of precursor lesions, such as pancreatic intraepithelial neoplasia (PanIN). Progression to PDAC is frequently associated with mutations in the tumor suppressor TP53 , presumably via disrupting p53-mediated cellular senescence of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4b17f3b2-1e7c-5a04-b862-8c68f4e2a2fb
DOI: 10.1101/2024.05.29.595146

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug-Induced p53 Activation Limits Pancreatic Cancer InitiationDOI 10.1101/2024.05.29.595146Read

Multifaceted role for p53 in pancreatic cancer suppressionSemantic proximity Read

p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.Semantic proximity Read

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read

The biological features of PanIN initiated from oncogenic Kras mutation in genetically engineered mouse models.Semantic proximity Read

CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2ASemantic proximity Read

Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancerSemantic proximity Read

SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in MiceSemantic proximity Read

TH301 Emerges as a Novel Anti-Oncogenic Agent for Human Pancreatic Cancer Cells: The Dispensable Roles of p53, CRY2 and BMAL1 in TH301-Induced CDKN1A/p21CIP1/WAF1 UpregulationSemantic proximity Read

Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development.Semantic proximity Read

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.Semantic proximity Read

Mir34a constrains pancreatic carcinogenesis.Semantic proximity Read

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.Semantic proximity Read